Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

March 11, 2024

https://www.globenewswire.com/news-release/2024/03/11/2843786/0/en/Journey-Medical-Corporation-Announces-Presentation-of-Data-from-Phase-1-Clinical-Trial-Assessing-the-Impact-of-DFD-29-Minocycline-Hydrochloride-Modified-Release-Capsules-40-mg-on-M.html

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues

Results indicate that DFD-29 can be safely used for up to 16 weeks with no detectable effects on microbiota in the skin, GI tract, or vagina

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.